Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
---|---|---|---|---|---|---|
2012-09-11 | Arsanis Biosciences (Austria) | €1.54 million | grant | Austrian Research Promotion Agency (Austria) | Infectious diseases | Grant |
2012-09-11 | Arsanis Biosciences (Austria) | € 4.55 million | grant | Austrian Research Promotion Agency (Austria) - European Eurostars Programme (EU) | Infectious diseases | Grant |
2012-09-07 | Biotie Therapies (Finland) | € 30 million | private placement | Lundbeck (Denmark) | Neurodegenerative diseases - Mental diseases | Private placement |
2012-09-06 | Karus Therapeutics (UK) | $7.6 million | series B financing round | SV Life Sciences (UK-USA) New Leaf Ventures (USA) Novo A/S (Denmark) International Biotechnology Trust (UK) IP Group (UK) a number of Angel investors |
Cancer - Oncology - Inflammatory diseases | Fundraising |
2012-09-05 | F2G (UK) | $30 Million (€ 23.75 million) | financing round | Advent Life Sciences Novartis Bioventures (Switzerland) Sunstone Capital Merifin Capital K Nominees Astellas Venture Fund |
Infectious diseases | Fundraising |
2012-09-04 | Theravectys (France) | € 7.48 million | fundraising | private investors including Guy Paillaud former executive manager of Promodes John Pieters, former CEO of Amgen France some of the company's historical investors and 10 new private investors, which include the Tethys fund (Bettenfourt family), Philippe Oddo and Richard Hennessy. |
Infectious diseases | Fundraising |
2012-09-04 | Laurantis Pharma (Finland) | € 5.64 million | Broadview Ventures (USA) - Inveni Capital - Aloitusrahasto Vera - Helsinki University Funds (Finland) - Veritas | Immunological diseases - Inflammatory diseases | Fundraising | |
2012-09-03 | to-BBB technologies (The Netherlands) | € 1.25 million | grant | Ophtalmalogical diseases - Genetic diseases - Rare diseases | Grant | |
2012-08-24 | Wilex (Germany) | € 23.9 million | private placement | UCB Pharma (Belgium) - dievini Hopp BioTech (Germany) - other existing shareholders | Cancer - Oncology | Private placement |
2012-08-03 | Biotie Therapies (Finland) | up to € 20 million | standby equity | Yorkville Advisors LLC (USA) | Neurodegenerative diseases - Psychiatric diseases | Fundraising |
2012-08-03 | Genfit (France) | €2 million | bond loan | Cardiovascular diseases - Metabolic diseases - Liver diseases | Fundraising | |
2012-08-02 | Summit (UK) | up to £150,000 | grant | Technology Strategy Board (UK) | Neurodegenerative diseases | Grant |
2012-08-01 | Pharming (The Netherlands) | up to €10 Million | equity working capital facility | Kingsbrook Opportunities Master Fund LP - other institutional investors | Rare diseases - Genetic diseases | Fundraising |
2012-07-31 | Silence Therapeutics (UK) | £5.45 million | fundraising through the issue of new ordinary shares | Private placement | ||
2012-07-30 | Vaccibody (Norway) | 875 000 € | share issue | The Norwegian Radium Hospital Research Foundation (Norway) - Sarsia Seed (Norway) - additional 9 investors | Infectious diseases | Fundraising |
2012-07-24 | Oxford Gene Technology (UK) | €3 million | grant | Infectious diseases | Grant | |
2012-07-23 | Cell Medica (UK) | £24 million (€30.8 million) | financing round | Imperial Innovations (UK) Invesco Perpetual (UK) the Cancer Prevention and Research Institute of Texas (CPRIT) (USA) |
Cancer - Oncology - Infectious diseases - Transplantation | Fundraising |
2012-07-23 | Oxford BioMedica (UK) | $125,000 (€103 310) | award | the Foundation Fighting Blindness (FFB) (USA) | Ophtalmological diseases - Rare diseases - Genetic diseases | Subvention |
2012-07-17 | Domain Therapeutics (France) | € 2 million | funding round | Seventure Partners (France) - SODIV (France) - AIRFI (Alsace Inter Regio Fonds d’Investissement) (France) - IP Growth - Auriga Partners (France) - Sam Eletr, the Chairman of the Board | Fundraising | |
2012-07-10 | Hemarina (France) | €6.3 million | series B financing round | Inserm Transfert Initiative (France) Finistère Angels (France) Armor Angels (France) XMP (France) Arkéa Capital Investissement (France) a family office represented and mandated by Maurice Lesaffre |
Transplantation - Technology - Services | Fundraising |